





















































































































<b>Questions</b>
1- Can you specify, what was the expected outcome from Pharmacoeconomic evaluation unit?
2- After 3 years from the guidelines issuance, you can score the outcome vs what was expected as? (5 scale choices) <ul style="list-style-type: none"> <li>- strongly satisfied with outcome</li> <li>- satisfied with outcome</li> <li>- neutral</li> <li>- Dissatisfied with outcome</li> <li>- strongly dissatisfied with outcome</li> </ul>
3- Did you find that CE is the most important parameter in reimbursement decision making?
4- If answer of 3 was no, what is the most important parameter the? <ul style="list-style-type: none"> <li>- Budget</li> <li>- Social aspects</li> <li>- Affordability</li> <li>- Other (specify)</li> </ul>
5- Moving towards Universal Health Coverage as part of WHO roadmap, How do you see the Pharmacoeconomic evaluation supporting the decision for: <ul style="list-style-type: none"> <li>- Inclusion</li> <li>- Pricing</li> <li>- Budget allocation</li> <li>- Others (Specify)</li> </ul>
6- What was the effect of deploying pharmacoeconomic evaluation on patients' medication access?
7- Did you face difficulty in choosing of comparator for a drug that requires pharmacoeconomic evaluation, if yes Which procedure are you following to evaluate the Pharmacoeconomic?
8- What are the main challenges you faced upon analyzing the cost effectiveness of drug?
9- Considering cost effectiveness threshold, which is better to consider DALY or QALY?
10- What are the next steps for the future pharmacoeconomics in Egypt?